Payment overview · 2025
General Payments
$1,763.38
73 reported records · 21 companies
Healthcare provider profile · identity verified
Eugene C. Lai, M.D., PH.D
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology · HOUSTON, TX · NPI 1790871002
Verified facts
What the public records show
CMS Open Payments records show Eugene C. Lai, M.D., PH.D received $1,763.38 in general payments during 2025 across 73 reported records.
Lilly USA, LLC accounted for 15.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 23 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Gocovri, Ingrezza, Nuplazid, Rexulti, Vumerity.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BOTOX as an associated drug or biological on 140321 records involving 30103 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Botox by this doctor in 2024.
ACADIA Pharmaceuticals Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUPLAZID as an associated drug or biological on 20845 records involving 6448 distinct recipient NPIs. Public Medicare Part D data also shows 94 claims for Nuplazid by this doctor in 2024.
Amneal Pharmaceuticals LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported RYTARY as an associated drug or biological on 200 records involving 121 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Rytary by this doctor in 2024.
Biogen, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VUMERITY as an associated drug or biological on 16193 records involving 4044 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Vumerity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Rexulti by this doctor in 2024.
MDD US Operations, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Gocovri as an associated drug or biological on 3202 records involving 1029 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Gocovri by this doctor in 2024.
Neurocrine BioSciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INGREZZA as an associated drug or biological on 126456 records involving 27390 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Ingrezza by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Rexulti by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $280.06 | 15.9% | 10 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $201.53 | 11.4% | 8 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $192.41 | 10.9% | 8 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $143.71 | 8.2% | 7 | 2025 |
| Supernus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $112.98 | 6.4% | 5 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $109.93 | 6.2% | 5 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $103.46 | 5.9% | 4 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $96.00 | 5.4% | 4 | 2025 |
| HOSPIRA, INC. | Unresolved — no canonical attribution shown | $66.23 | 3.8% | 3 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $66.02 | 3.7% | 3 | 2025 |
| MDD US Operations, LLC | Unresolved — no canonical attribution shown | $60.48 | 3.4% | 3 | 2025 |
| CSL Behring | Unresolved — no canonical attribution shown | $46.84 | 2.7% | 1 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $42.61 | 2.4% | 2 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $42.32 | 2.4% | 2 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $40.89 | 2.3% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $33.17 | 1.9% | 1 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $31.90 | 1.8% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $27.39 | 1.6% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $26.17 | 1.5% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $22.11 | 1.2% | 1 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $17.17 | 1.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,716.54 | 72 |
| Education | $46.84 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $280.06 | 10 | 2025 |
Source payment records
|
|||||
| AMYVID Normalized: amyvid |
Drug | Lilly USA, LLC | $210.61 | 8 | 2025 |
Source payment records
|
|||||
| OCTAGAM IMMUNE GLOBULIN (HUMAN) Normalized: octagam immune globulin human |
Drug | HOSPIRA, INC., PFIZER INC. | $209.94 | 10 | 2025 |
Source payment records
|
|||||
| PANZYGA Normalized: panzyga |
Biological | HOSPIRA, INC., PFIZER INC. | $209.94 | 10 | 2025 |
Source payment records
|
|||||
| UPLIZNA Normalized: uplizna |
Biological | Amgen Inc. | $201.53 | 8 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $192.41 | 8 | 2025 |
Source payment records
|
|||||
| Qelbree Normalized: qelbree |
Drug | Supernus Pharmaceuticals, Inc. | $112.98 | 5 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $109.93 | 5 | 2025 |
Source payment records
|
|||||
| VYALEV Normalized: vyalev |
Drug | ABBVIE INC. | $103.46 | 4 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $96.00 | 4 | 2025 |
Source payment records
|
|||||
| Gocovri Normalized: gocovri |
Drug | MDD US Operations, LLC | $60.48 | 3 | 2025 |
Source payment records
|
|||||
| CREXONT Normalized: crexont |
Drug | Amneal Pharmaceuticals LLC | $47.05 | 2 | 2025 |
Source payment records
|
|||||
| Hizentra Normalized: hizentra |
Biological | CSL Behring | $46.84 | 1 | 2025 |
Source payment records
|
|||||
| ULTOMIRIS Normalized: ultomiris |
Biological | Alexion Pharmaceuticals, Inc. | $42.32 | 2 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $40.89 | 1 | 2025 |
Source payment records
|
|||||
| General - DBS Normalized: general dbs |
Device | Boston Scientific Corporation | $33.17 | 1 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $31.90 | 2 | 2025 |
Source payment records
|
|||||
| INFINITY Normalized: infinity |
Device | Abbott Laboratories | $27.39 | 1 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $26.17 | 1 | 2025 |
Source payment records
|
|||||
| HYQVIA Normalized: hyqvia |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $22.11 | 1 | 2025 |
Source payment records
|
|||||
| ONGENTYS Normalized: ongentys |
Drug | Amneal Pharmaceuticals LLC | $18.97 | 1 | 2025 |
Source payment records
|
|||||
| TYSABRI Normalized: tysabri |
Biological | Biogen, Inc. | $17.17 | 1 | 2025 |
Source payment records
|
|||||
| VUMERITY Normalized: vumerity |
Drug | Biogen, Inc. | $17.17 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Gocovri gocovri |
2025 | Gocovri | 2024 | 41 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| INGREZZA ingrezza |
2025 | Ingrezza | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NUPLAZID nuplazid |
2025 | Nuplazid | 2024 | 94 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VUMERITY vumerity |
2025 | Vumerity | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | BOTOX open payments reported associated product |
CMS Open Payments — General Payments 140321 supporting records · 30103 recipient NPIs · example record 1201352642 |
Botox · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| ACADIA Pharmaceuticals Inc Exact reporting entity; no affiliate inference |
2025 | NUPLAZID open payments reported associated product |
CMS Open Payments — General Payments 20845 supporting records · 6448 recipient NPIs · example record 1247763852 |
Nuplazid · 2024 Exact normalized brand match · 1 Part D row |
94 | 11 |
| Amneal Pharmaceuticals LLC Exact reporting entity; no affiliate inference |
2025 | RYTARY open payments reported associated product |
CMS Open Payments — General Payments 200 supporting records · 121 recipient NPIs · example record 1220526035 |
Rytary · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Biogen, Inc. Exact reporting entity; no affiliate inference |
2025 | VUMERITY open payments reported associated product |
CMS Open Payments — General Payments 16193 supporting records · 4044 recipient NPIs · example record 1208299697 |
Vumerity · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| MDD US Operations, LLC Exact reporting entity; no affiliate inference |
2025 | Gocovri open payments reported associated product |
CMS Open Payments — General Payments 3202 supporting records · 1029 recipient NPIs · example record 1241843637 |
Gocovri · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| Neurocrine BioSciences, Inc. Exact reporting entity; no affiliate inference |
2025 | INGREZZA open payments reported associated product |
CMS Open Payments — General Payments 126456 supporting records · 27390 recipient NPIs · example record 1242766729 |
Ingrezza · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Carbidopa-Levodopa | Carbidopa/Levodopa | 601 | 166 |
| Donepezil Hcl | Donepezil Hcl | 493 | 153 |
| Sertraline Hcl | Sertraline Hcl | 316 | 90 |
| Memantine Hcl | Memantine Hcl | 243 | 72 |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 206 | 60 |
| Clonazepam | Clonazepam | 161 | 32 |
| Trazodone Hcl | Trazodone Hcl | 124 | 35 |
| Gabapentin | Gabapentin | 105 | 32 |
| Nuplazid | Pimavanserin Tartrate | 94 | 11 |
| Amantadine | Amantadine Hcl | 84 | 24 |
| Levetiracetam | Levetiracetam | 70 | 19 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 65 | 21 |
| Quetiapine Fumarate | Quetiapine Fumarate | 62 | 15 |
| Baclofen | Baclofen | 59 | 16 |
| Primidone | Primidone | 57 | 18 |
| Escitalopram Oxalate | Escitalopram Oxalate | 55 | 18 |
| Gocovri | Amantadine Hcl | 41 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 39 | 12 |
| Propranolol Hcl Er | Propranolol Hcl | 38 | 11 |
| Rasagiline Mesylate | Rasagiline Mesylate | 36 | suppressed |
| Rivastigmine | Rivastigmine | 36 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 28 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 28 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 27 | suppressed |
| Mirtazapine | Mirtazapine | 26 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 26 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 23 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 20 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 20 | suppressed |
| Rytary | Carbidopa/Levodopa | 18 | suppressed |
| Rexulti | Brexpiprazole | 17 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 16 | suppressed |
| Lorazepam | Lorazepam | 16 | suppressed |
| Prednisone | Prednisone | 16 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 16 | suppressed |
| Botox | Onabotulinumtoxina | 15 | suppressed |
| Lacosamide | Lacosamide | 15 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 14 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 14 | suppressed |
| Carbamazepine | Carbamazepine | 13 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 13 | suppressed |
| Vumerity | Diroximel Fumarate | 13 | suppressed |
| Alprazolam | Alprazolam | 12 | suppressed |
| Carbidopa-Levodopa-Entacapone | Carbidopa/Levodopa/Entacapone | 12 | suppressed |
| Gamunex-C | Immune Globul G/Gly/Iga Avg 46 | 12 | suppressed |
| Ingrezza | Valbenazine Tosylate | 12 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 12 | suppressed |
| Neupro | Rotigotine | 12 | suppressed |
| Pramipexole Er | Pramipexole Di-Hcl | 12 | suppressed |
| Topiramate | Topiramate | 12 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,763.38 · 73 records | Lilly USA, LLC | AMYVID, AUSTEDO XR, CREXONT, General - DBS, Gocovri, HYQVIA, Hizentra, INFINITY, INGREZZA, KISUNLA, Leqembi, NUPLAZID, OCTAGAM IMMUNE GLOBULIN (HUMAN), ONGENTYS, PANZYGA, Qelbree, REXULTI, TYSABRI, ULTOMIRIS, UPLIZNA, VUMERITY, VYALEV, VYEPTI | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Gocovri play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error